UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (4351) 4351
Newsletter (52) 52
Newspaper Article (5) 5
Book Chapter (4) 4
Magazine Article (4) 4
Conference Proceeding (3) 3
Publication (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4192) 4192
female (3146) 3146
male (3033) 3033
leucovorin - administration & dosage (3001) 3001
middle aged (2924) 2924
science & technology (2906) 2906
life sciences & biomedicine (2890) 2890
aged (2712) 2712
antineoplastic combined chemotherapy protocols - therapeutic use (2610) 2610
fluorouracil - administration & dosage (2422) 2422
adult (2343) 2343
oncology (2267) 2267
antineoplastic combined chemotherapy protocols - adverse effects (2259) 2259
leucovorin - adverse effects (1563) 1563
fluorouracil - adverse effects (1553) 1553
colorectal neoplasms - drug therapy (1466) 1466
treatment outcome (1209) 1209
leucovorin - therapeutic use (1163) 1163
chemotherapy (1072) 1072
antineoplastic combined chemotherapy protocols - administration & dosage (1054) 1054
organoplatinum compounds - administration & dosage (1011) 1011
colorectal cancer (983) 983
colorectal neoplasms - pathology (905) 905
camptothecin - analogs & derivatives (882) 882
drug administration schedule (853) 853
cancer (838) 838
leucovorin (835) 835
fluorouracil - therapeutic use (808) 808
organoplatinum compounds - adverse effects (729) 729
aged, 80 and over (690) 690
adenocarcinoma - drug therapy (670) 670
camptothecin - administration & dosage (670) 670
disease-free survival (657) 657
neoplasm staging (562) 562
survival rate (556) 556
methotrexate - administration & dosage (550) 550
neoplasm metastasis (537) 537
methotrexate - adverse effects (526) 526
care and treatment (497) 497
survival analysis (489) 489
oxaliplatin (488) 488
metastasis (461) 461
infusions, intravenous (454) 454
organoplatinum compounds - therapeutic use (453) 453
5-fluorouracil (444) 444
fluorouracil (435) 435
pharmacology & pharmacy (433) 433
medicine & public health (426) 426
retrospective studies (424) 424
chemotherapy, adjuvant (408) 408
colorectal neoplasms - mortality (405) 405
camptothecin - adverse effects (399) 399
liver neoplasms - secondary (394) 394
colonic neoplasms - drug therapy (385) 385
dose-response relationship, drug (372) 372
bevacizumab (371) 371
abridged index medicus (367) 367
combined modality therapy (357) 357
prognosis (350) 350
research (350) 350
deoxycytidine - analogs & derivatives (342) 342
cisplatin - administration & dosage (340) 340
liver neoplasms - drug therapy (340) 340
stomach neoplasms - drug therapy (335) 335
follow-up studies (328) 328
prospective studies (328) 328
surgery (327) 327
irinotecan (303) 303
drug therapy, combination (302) 302
adolescent (299) 299
antimetabolites, antineoplastic - adverse effects (296) 296
antimetabolites, antineoplastic - administration & dosage (289) 289
adenocarcinoma - pathology (288) 288
drug therapy (283) 283
time factors (272) 272
antineoplastic agents - adverse effects (266) 266
camptothecin - therapeutic use (264) 264
disease progression (263) 263
deoxycytidine - administration & dosage (255) 255
clinical trials (251) 251
kaplan-meier estimate (247) 247
rectal neoplasms - drug therapy (243) 243
tegafur - administration & dosage (240) 240
administration, oral (233) 233
methotrexate - therapeutic use (230) 230
analysis (227) 227
antineoplastic agents (224) 224
antineoplastic agents - administration & dosage (224) 224
hematology, oncology and palliative medicine (218) 218
adenocarcinoma - mortality (214) 214
cancer research (212) 212
remission induction (211) 211
colonic neoplasms - pathology (204) 204
health aspects (204) 204
antibodies, monoclonal - administration & dosage (203) 203
toxicity (203) 203
adenocarcinoma - secondary (201) 201
antimitotic agents (201) 201
antimetabolites, antineoplastic - therapeutic use (198) 198
neutropenia - chemically induced (198) 198
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4121) 4121
Japanese (215) 215
Chinese (55) 55
German (50) 50
French (47) 47
Italian (19) 19
Spanish (16) 16
Russian (9) 9
Hungarian (5) 5
Portuguese (5) 5
Dutch (4) 4
Korean (4) 4
Danish (3) 3
Bulgarian (1) 1
Czech (1) 1
Norwegian (1) 1
Persian (1) 1
Polish (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the National Comprehensive Cancer Network, ISSN 1540-1405, 07/2014, Volume 12, Issue 7, pp. 1028 - 1059
The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance,... 
Life Sciences & Biomedicine | Oncology | Science & Technology | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Colonic Neoplasms - drug therapy | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - therapeutic use | Bevacizumab | Colonic Neoplasms - surgery | Fluorouracil - therapeutic use | Deoxycytidine - therapeutic use | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Angiogenesis Inhibitors - therapeutic use | Deoxycytidine - adverse effects | Leucovorin - therapeutic use | Cetuximab | Liver Neoplasms - secondary | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Camptothecin - therapeutic use | Fluorouracil - analogs & derivatives | Membrane Proteins - genetics | Liver Neoplasms - drug therapy | Liver Neoplasms - surgery | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease Progression | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | GTP Phosphohydrolases - genetics | Proto-Oncogene Proteins B-raf - genetics | Colonic Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Deoxycytidine - analogs & derivatives | Organoplatinum Compounds - adverse effects
Journal Article
The New England journal of medicine, ISSN 1533-4406, 10/2014, Volume 371, Issue 17, pp. 1609 - 1618
... and overall survival, with an increase in some side effects. 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Follow-Up Studies | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Bevacizumab | Fluorouracil - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Neoplasm Metastasis - drug therapy | Colorectal Neoplasms - drug therapy | Adult | Female | Leucovorin - therapeutic use | Liver Neoplasms - secondary | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Camptothecin - therapeutic use | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Organoplatinum Compounds - adverse effects | Treatment outcome | Care and treatment | Analysis | Colorectal cancer | Dosage and administration | Leucovorin | Fluorouracil | Colorectal carcinoma | Diarrhea | Metastasis | Survival | Patients | Clinical outcomes | Metastases | Irinotecan | Stomatitis | Chemotherapy | Neurotoxicity | Oxaliplatin | Monoclonal antibodies | Vascular endothelial growth factor | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 06/2017, Volume 317, Issue 23, pp. 2392 - 2401
IMPORTANCE: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - therapeutic use | United States | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Cetuximab - therapeutic use | Cetuximab - adverse effects | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Camptothecin - adverse effects | Kaplan-Meier Estimate | Treatment Outcome | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - secondary | Aged | Genes, ras | Organoplatinum Compounds - adverse effects | Chemotherapy | Usage | Care and treatment | Research | Colorectal cancer | Cancer | Drugs | Medical research | Colorectal carcinoma | Clinical trials | Cytotoxicity | Patients | Survival | K-Ras protein | Bevacizumab | Metastases | Survival analysis | Irinotecan | Oxaliplatin | Monoclonal antibodies | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Annals of oncology, ISSN 0923-7534, 11/2009, Volume 20, Issue 11, pp. 1842 - 1847
Journal Article
Journal Article
Journal Article
Blood, ISSN 1528-0020, 06/2001, Volume 97, Issue 11, pp. 3370 - 3379
Journal Article
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 11/2010, Volume 28, Issue 31, pp. 4697 - 4705
Purpose Panitumumab, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody that improves progression-free survival (PFS), is approved... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Leucovorin - administration & dosage | Predictive Value of Tests | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Chemotherapy, Adjuvant | Colorectal Neoplasms - metabolism | Colorectal Neoplasms - mortality | Drug Administration Schedule | Kaplan-Meier Estimate | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Infusions, Intravenous | Mutation | Colorectal Neoplasms - pathology | Neoplasm Staging | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article